Woolcott Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Yves Brault Shareholder of: Pfizer France, Employee of: Pfizer France, Lisy Wang Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Meriem Kessouri Shareholder of: Pfizer France, Employee of: Pfizer France
DOI: 10.1136/annrheumdis-2020-eular.949

FRI0336

CONCOMITANT USE OF BIOLOGIC DMARDS WITH CSDMARDS INCREASES DRUG RETENTION RATE AND IMPROVES TREATMENT RESPONSE IN THE PSORIATIC ARTHRITIS. HUR-BIO REAL LIFE RESULTS

E. Duran¹, E. Bilgin¹, E. C. Bolek¹, G. K. Yardımcı¹, B. Farisoğulları¹, L. Kılıç¹, A. Akdoğan¹, O. Karadag¹, Ş. Arpaş Bilgen¹, S. Kiraz¹, A. İ. Ertenli¹, U. Kalyoncu¹. ¹Hacettepe University Medical School Internal Medicine, Rheumatology, Ankara, Turkey

Background: For inflammatory arthritis, drug retention is accepted as an important indicator of the effectiveness and safety of biological drugs.

Objectives: The objective of this study was to determine of the effects first and overall bDMARD drug retention rate during concomitant csDMARD in psoriatic arthritis (PsA).

Methods: HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a prospective, single center database of biological treatments since 2005. All PsA patients (469) who enrolled in HUR-BIO registry and prescribed at least once biologic DMARD (bDMARD) were included in the study. The subjects were divided into two groups depending on whether or not to use csDMARDs (methotrexate, sulphasalazine or leflunomide) at the last control visit. Demographic, clinical and therapeutic data were collected from this database. Baseline disease activity before the first bDMARD initiation was assessed with DAPSA and PsAID-12.

Table. Demographics, baseline and follow-up clinical characteristics of PsA patients

	With concomitant csDMARD n=288	Without concomitant csDMARD n=167	p
Age (mean, SD)	48.9 (12.1)	45.1 (12.4)	0.002
Female n (%)	204 (70.8)	113 (67.7)	0.48
PsA disease duration (med, IQR)	7 (13)	7 (14.5)	0.53
Age at PsA diagnosis (mean, SD)	39 (11.7)	40.8 (12.9)	0.81
BMI (mean, SD)	29.6 (6.0)	29.2 (5.9)	0.53
Axial involvement n (%)	68 (34.0)	37 (44.6)	0.09
HLA-B 27 (+) n (%)	21/76 (27.6)	17/69 (24.6)	0.68
Duration of use first bDMARD (months) (med, IQR)	22.4 (51.3)	14.1 (31.4)	0.003
Duration of use overall bDMARD (months) (med, IQR)	56.8 (69.4)	24.4 (57.7)	<0.001
Switching bDMARD (+) n (%)	148 (52.5)	71 (42.8)	0.04
Initial DAPSA ¹ (med, IQR)	19.4 (11.7)	17.3 (10.2)	0.04
Initial PsAID ² (med, IQR)	5.7 (3)	5.6 (2.8)	0.55
Final visit PsAID ³ (med, IQR)	2.8 (3.8)	2 (5.7)	0.41
Final visit DAPSA ⁴ (med, IQR)	10.2 (12.4)	12.5 (12.5)	0.01
Remission (n, %)	61 (23.9)	27 (17.6)	0.13
Low disease activity	111 (43.5)	59 (38.6)	
Moderate disease activity	72 (28.2)	58 (37.9)	
High disease activity	11 (4.3)	9 (5.9)	

¹: n=249, ²: n=214, ³: n=109, ⁴: n=408

p<0.001

p=0.003

Results: HUR-BIO PsA registry included 469 PsA patients. Baseline, clinical characteristics and follow-up parameters were given in Table. The using overall bDMARD were adalimumab 294 (62.0%), etanercept 135 (28.8%), infliximab 119 (25.4%), certolizumab pegol 107 (22.8%), secukinumab 67 (14.3%), golimumab 58 (12.4%), ustekinumab 25 (5.3%) and tofacitinib 11 (2.3%). Two hundred eighty eight (61.4%) patients used concomitant cDMARDs [methotrexate 176 (37.5%), leflunomide 94 (20.0%), sulphasalazine 35 (7.5%) and two csDMARD combination 17 (3.6%)]. The first-year retention rate of first bDMARD with or without concomitant csDMARDs were 88% and 80%, respectively. The median duration of first bDMARD retention with or without concomitant csDMARDs were 131.7 and 91.4 months, respectively (Figure). The first-year retention rate of overall bDMARDs with or without concomitant csDMARDs were 92% and 85%, respectively. The median drug retention rate of overall bDMARD in using csDMARD and not using csDMARD were 141.5 and 131.5 months, respectively. Retention rates (both for first bDMARD and overall bDMARDs) were significantly higher in concomitant csDMARDs using group (p=0.003 for first bDMARD retention, p<0.001 for overall bDMARDs retention, log-rank; Figure). In concomitant csDMARD using group, no differences were identified methotrexate or other csDMARDs.

Conclusion: In this study, csDMARDs, either methotrexate or leflunomide/sulphasalazine have additional effect for both retention rate and treatment response of bDMARDs. On the other hand, using bDMARD monotherapy is relatively higher than rheumatoid arthritis (1).

Figure. Drug retention rate of the first bDMARD and overall bDMARDs according to concomitant csDMARD use (csDMARD:conventional synthetic Disease Modifying Antirheumatic Drug)

Disclosure of Interests: Emine Duran: None declared, Emre Bilgin: None declared, Ertugrul Cagri Bolek: None declared, Gözde Kübra Yardımcı: None declared, Bayram Farisoğulları: None declared, Levent Kılıç: None declared, Ali Akdoğan: None declared, Omer Karadag: None declared, Şule Arpaş Bilgen: None declared, Sedat Kiraz: None declared, Ali İhsan Ertenli: None declared, Umut Kalyoncu Consultant of: Abbvie, Amgen, Janssen, Lilly, Novartis, UCB
DOI: 10.1136/annrheumdis-2020-eular.4782

FRI0337

REAL WORLD SECUKINUMAB DRUG-SURVIVAL IN PSORIATIC ARTHRITIS

T. Eviatar^{1,2}, D. Zisman^{3,4}, M. Lidar^{1,5}, T. Reitblat⁶, A. Balbir-Gurman⁷, O. Elkayam^{1,2}. ¹Tel Aviv University, Tel Aviv-Yafo, Israel; ²Ichilov, Tel Aviv-Yafo, Israel; ³The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel; ⁴Carmel Medical Center, Haifa, Israel; ⁵Sheba Medical Center - Lipids, Ramat Gan, Israel; ⁶Barzilai Medical Center, Ashkelon, Israel; ⁷Rambam Health Care Campus, Haifa, Israel

Background: Secukinumab (Cosentyx) is a human IgG1 monoclonal antibody that selectively binds to and neutralizes IL-17A. Several prospective randomized control trials have demonstrated the efficacy and safety of secukinumab in PsA, but there is a paucity of real life data in the PsA population.

Objectives: To prospectively study secukinumab's safety, efficacy, and tolerability in the cohort of PsA patients from the Israeli registry of inflammatory diseases.

Methods: PsA patients fulfilling the CASPAR criteria from the Israeli registry of inflammatory diseases were included in the analysis, from 2010 to November 2019. The primary end point was secukinumab drug survival compared to other available TNFi drug. Bivariate and multivariate analysis of the factors that affect the drug event free survival was done by cox regression analysis. Drug survival according to treatment line (all treatment lines, or 2nd and above treatment lines) was examined using Kaplan-Meier curves.

Results: Four hundred and four PsA patients were included, which had 709 treatment episodes (initiations) during the study period. Ninety patients had been treated with secukinumab (22%). Secukinumab treated patients were significantly older at time of initiation of treatment, and disease duration was longer. Secukinumab was more likely to be a second, third or fourth line of treatment than the TNFi. Time to an inefficacy event was longer for secukinumab than any other anti-TNF treatment. As a first line treatment secukinumab had drug survival similar to other TNFi. As a second or third line treatment, secukinumab had a better drug survival than other TNFi. Methotrexate did not have a significant effect on inefficacy event rate in combination treatment with secukinumab. Secukinumab, as infliximab and golimumab, was as effective in the higher BMI group as it was in the normal weight to obese groups. Smokers (current or past) did better on secukinumab than on TNFi. Secukinumab had a similar rate of adverse events compared to TNFi.

Conclusion: In this multicenter real world study, secukinumab had a comparable drug survival to TNFi. As a second and beyond line of treatment secukinumab had a better drug survival and lower HR for an inefficacy event. IL-17 inhibition is an effective mechanism of action to treat PsA in real life, and should be used more frequently as a first and second line treatment.

Tables and a graph: